As expected, patients with NAFLD had higher ALT, AST, GGT, ALP, UA, FBG, FINS, HOMA-IR, TG, TC, FFA, LDL-C and APOB than non-NAFLD group, while HDL-C and APOA1 were lower than non-NAFLD group. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.